Patents - Sandoz Ltd v Bristol-Myers Squibb
Jane Lambert Patents Court (Mr Justice Meade) Sandoz Ltd and another v Bristol-Myers Squibb Holdings Ireland (Unlimited) Company [2022] EWHC 822 (Pat) (7 April 2022) These were two separate actions for the revocation of a European patent (UK) 1 427 415 B1 (“the patent”) . The patent was held by Bristol-Myers Squibb Holdings Ireland (Unlimited) Company ("BMS") and the proceedings were brought by Sandoz Limited (“Sandoz”) and Teva Pharmaceutical Industries Limited (“Teva”). BMS counterclaimed against both claimants for infringement which was admitted subject to the validity of the patent. The actions came on for trial before Mr Justice Mrade between 31 Jan and 10 Feb 2022. By para [257] of his judgment of 7 April 2022 he held that the patent was invalid for lack of plausibility and technical contribution ( see Sandoz Ltd v Bristol-Myers Squib Holdings Ireland (Unlimited) Company [2022] EWHC 822 (Pat) (7 April 2022...